GlassScriptPhysician profile
Hailey M Arens
NPI 1700351376
$7,588.74
in general payments reported to CMS, 2019-2025
25 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $1,737 · 2023: $2,574 · 2024: $1,335 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,846 · Education: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,845.69 |
| Education | $444.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,231.32 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $906.69 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $846.82 | 2022-2025 | |
| Lilly USA, LLC | $792.73 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $687.42 | 2021-2025 | Ilumya, Winlevi, Blu-U |
| Janssen Biotech, INC. | $626.03 | 2021-2025 | Tremfya |
| Incyte Corporation | $446.99 | 2022-2024 | Opzelura |
| Genzyme Corporation | $384.21 | 2021-2025 | |
| Amgen INC. | $307.56 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $265.56 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $210.05 | 2021-2025 | Adbry |
| Galderma Laboratories, L.P. | $194.51 | 2021-2025 | Nemluvio |
| Pfizer INC. | $172.45 | 2022-2025 | |
| Merz North America, INC. | $161.39 | 2024 | |
| Ucb, INC. | $136.51 | 2023-2025 | Bimzelx, Cimzia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $43.50 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $34.00 | 2024 | Ycanth |
| Allergan, INC. | $24.43 | 2022 | |
| Revance Therapeutics, INC. | $21.79 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.88 | 2023 | Spevigo |
| Kyowa Kirin, INC. | $16.50 | 2023 | Poteligeo |
| Paratek Pharmaceuticals, INC. | $15.89 | 2022 | |
| Organon LLC | $15.80 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.15 | 2024 | Jublia |
| Arcutis Biotherapeutics, INC. | $13.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Arens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.